Placeholder

In the Boardroom

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

From defining and redefining organizational business models for big pharma, biotech, and emerging pharma to tactical decisions related to developing generic defense strategies to improving communications and corporate reputation plans to grappling with technology issues, today’s pharmaceutical leaders are relying on business-savvy solutions.

Sidebars:
M&A Activity
Defending Brand Revenue: Pharmaceutical Life-cycle Management Planning
Big Pharma Business Models Are Evolving
Managing M&A Honeymoon Blues
Top Pharmaceutical Companies Failing to Deliver Major New Products
The Emerging Global Labor Market: Demand for Offshore Talent in Pharmaceutical Services
Midwest will be next biotech hotbed
Major Pharma Invests in Biotech
The Centient Biotech Top 10
Biotech — Beyond Borders 2005
Study Reveals $20 Billion in Untapped Generic Drug Savings
More Than 40 Major Patents Expire and Drive Growth to 2009
Biogenerics: An Emerging Global Market
Software Leads as Fastest Growing IT Spending Category for Life-Sciences Companies
U.S. Adults Strongly Favor and Value New Medical Technologies in Their Doctor’s Offices
Media Coverage of Prescription Drug Recalls and Recent Lawsuit Judgments May Have Negative Impact on Clinical-Trial Participation
Safeguarding the Pharmaceutical Supply Chain and Demonstrating Transparency Seen as Critical to Building Public Confidence and Managing Business Risks

Thought Leaders
A.N. Aditya. Frost & Sullivan
Paul W. Allen. Clarkston Consulting
Ellen Barrosse. Synchrogenix Information Strategies Inc.
Eric Bolesh. Cutting Edge Information
Jeff Brady. Advanced Health Media
G. Steven Burrill. Burrill & Company
Daniel B. Carr, M.D. Javelin Pharmaceuticals Inc.
Glen de Vries. Medidata Solutions Worldwide
Cameron Durrant, M.D., MBA. PediaMed – The Pediatrics Company
Hakan S. Edstrom. Mannkind Corp.
Frank Eeckman, M.D., Ph.D. The Centient Biotech Investor
Mario Ehlers, M.D., Ph.D. Pacific Biometrics Inc.
Elio Evangelista. Cutting Edge Information
James Featherstone. Wood Mackenzie
Paul E. Freiman. Neurobiological Technologies Inc.
Mark D. Gessler. Gene Logic Inc.
Mark Goldstone. Interbrand Wood
Marita Gomez. HealthInfo Direct LLC
Daniel E. Greenleaf. VioQuest Pharmaceuticals Inc.
Richard Greif. Opinion Dynamics Corp.
Jon Hess. Cutting Edge Information
R. Douglas Hulse. Hemispherx Biopharma Inc.
Eric Langer. BioPlan Associates Inc.
Pierre Laurin. ProMetic Life Sciences Inc.
Carolyn Buck Luce. Ernst & Young LLP
Maureen Mangiavas. The Hal Lewis Group Inc.
David McGirr. Cubist Pharmaceuticals Inc.
Ellen G. Miller. Biosector 2
Steve Miller, M.D. Express Scripts Inc.
Tim Noffke. Integrated Project Management Co. Inc.
Bernard Poussot. Wyeth Pharmaceuticals
Dr. Keith Redpath. Wood Mackenzie
Amanda C. Rhodes, MPH, CHES. MicroMass Communications Inc.
John Rhodes. Deloitte & Touche USA LLP
John Riabov. Windwood Consulting LLC
John Rothman, M.D. Advaxis
Greg Scott. Centient Consulting Inc.
Mollie Shields-Uehling. SAFE-BioPharma Association
Jean Stephenne. GlaxoSmithKline Biologicals
Harry A. Sweeney. Dorland Global Corp.
Roni Thaler. The Center for Information and Study on Clinical Research Participation (CISCRP)
Glenn Van Deusen. Parexel International
David Wood. Interbrand Wood
Kleanthis Xanthopoulos, Ph.D. Anadys Pharmaceuticals
Alex Zisson. Thomas, McNerney & Partners

FEEDBACK